dr d post ymb removed but reposted by philip:
Phillip2
dr d post ymb removed but reposted by philip:
Phillip2 hours ago
This was number 2 post on top by drD before it was removed. Sharing again.
Dr Kelly spoke about the London and the Berlin patients on the CC :
When he was announcing the NIH grant of $5Mllion to Dr Sacha’s of Leronlimab with vectors delivery and to have “the patient’s own immune cells produce Leronlimab “ .
The London patient and the Berlin patient had Leukemia and non-Hodgkin’s Lymphoma in advanced stages and they both became NED after their total bone marrow ablation and the transplant with the delta 32 mutation . This fact shows us the implications of what could be achieved for the cure of cancers and specifically hematopoietic/lymphatic cancers and most likely many others .
It’s a Huge step for Humanity
It’s not only the functional cure for HIV but the actual cure for cancer
The Grant by the NIH is an important acknowledgment of the scientific validity of Leronlimab .
As of right now , we are an Oncology company because we are actually studying how to replicate the results of these 2 patients.
Dr Kelly has said we would be an Oncology company .
And now we know why .
The science of Leronlimab is unique and a big part of the pathway to eradicate many diseases that have plagued humanity for centuries .
The time is Now
10
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
The Investor Storm Brewing Over Honeywell Aerospace There it is again, another industry heavyweight caught in a dizzying whirlwind of litigation. Honeywell Aerospace Inc. (NASDAQ:HONA), a name as established as an old boot in the business, now faces a class action lawsuit that's got investors frantically dusting off phone numbers for their attorneys. The Messy Allegations...
Continue Reading
University's Innovative Approach to Learning Alright, here's something you don't see every day. The University of Phoenix managed to snag some kudos from an academic journal for using AI and storytelling to teach environmental science. That's like hitting two bulls-eyes with one shot in the world of education. The recognition from Glacies for this Editor's Choice paper...
Continue Reading
A Star-Studded Fantasy Comes Alive Hong Kong isn't just about dim sum and skyline views—it's a magnet for celebrity showcases, and this time, Jackson Wang's pulling the strings. The guy's ventured beyond music and idol fame, diving head-first into creative visuals with his fantasy IP, "Under the Castle" (UTC). Pairing up with Ocean Park's Halloween Fest, he's cooked up...
Continue Reading
CVS Under Regulatory Spotlight for Fiduciary Breaches You'd think by now companies would have their fiduciary ducks in a row. But here we are, with CVS Health Corporation (NYSE: CVS) catching heat from the legal eagles over at Halper Sadeh LLC. The knife’s out for some of the big wigs – apparently, there's chatter they might’ve slipped on their duty to play nice...
Continue Reading
Diving Deep into the Krispy Kreme Allegations Look, this isn't your run-of-the-mill donut drama. When you hear rumblings of corporate missteps, especially ones that involve potential breaches of fiduciary duties, it's time to perk up those ears. Over at Krispy Kreme, Inc. (NASDAQ:DNUT), there's some heat in the kitchen, and it's not just from frying those glazed beauties....
Continue Reading
PACS Group: Legal Storm Brewing Welcome to the latest saga in the volatile theater of corporate governance. PACS Group, Inc., ticker symbol NYSE:PACS, is under the microscope, and not for debuting a groundbreaking product or hitting a stock milestone. Nope, instead we've got Halper Sadeh LLC out of New York investigating some possible hanky-panky from PACS directors and...
Continue Reading
Spotlight on Geron's Corporate Governance: What's Happening? The heat's been turned up on Geron Corporation this week, with Halper Sadeh LLC, an investor rights law outfit, digging into whether some folks at the helm have strayed from their fiduciary duties to the shareholders. Now, if you're holding onto NASDAQ:GERN stock or thinking about diving in, it's high time to...
Continue Reading
Ah, sunglasses—the quintessential accessory that screams both practicality and style. A million-dollar look without the million-dollar expense? That's where Quay comes in. They've been recognized by Expert Consumers, no less, as some of the best-in-class for affordable luxury eye candy out there—aimed at shoppers who want the designer vibe without the hemorrhaging...
Continue Reading
Top 5 Most Recently Viewed Articles
Auburn National Bancorporation's Q3 Earnings Overview Auburn National Bancorporation, Inc. recently announced its financial results for the third quarter of 2024. The report highlighted significant improvements in key financial metrics compared to the same quarter last year. Financial Performance Highlights For the third quarter of 2024, Auburn National Bancorporation...
Continue Reading
NEO Battery Materials Grants Incentive Stock Options TORONTO — NEO Battery Materials Ltd. (“NEO” or the “Company”) (TSX-V: NBM) (OTC: NBMFF), known for pioneering low-cost silicon anode materials, has recently announced the granting of incentive stock options to several of its directors and officers. This move allows them to acquire a total of 510,000 common...
Continue Reading
Introduction to a New Era in Software Development In a significant collaboration aimed at enhancing software development capabilities, Zventus, a prominent global consulting firm, has joined forces with the Ensenada Institute of Technology. This partnership marks an important milestone in connecting academic learning with crucial industry needs. The Purpose Behind the...
Continue Reading
Robert Reich's Perspective on Proposed Tax Cuts Renowned economist and former U.S. Secretary of Labor Robert Reich has voiced strong concerns regarding the tax reduction proposals from the administration led by Donald Trump. In a recent statement, Reich described the intended cuts as "an absolutely shameless giveaway" that could potentially escalate the federal deficit by...
Continue Reading
What's Eli Lilly Cooking Up? So, Eli Lilly is throwing some serious chips on the table with these new acquisitions. The pharma giant is snapping up not one, not two, but three companies—all to bolster its infectious disease game. Now, if you've been around the market block as long as I have, you know they aren't just doing this for fun. It's about strategic positioning,...
Continue Reading